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Urinary zinc excretion was monitored in anesthetized dogs before and during 4 hr after acute 
exposure to lead (doses: 0.3 mg Pb (as acetate)/kg as iv prime, followed by infusion of 0.057 
mg Pb/min; 3mg Pb/kg, followed by 0.57 mg Pb/min as infusion; or equimolar sodium acetate 
in the control group). Zinc excretion in time controls was relatively constant over the 4 hr. 
but it rose above baseline values an average of 140 ng/min in 0.3 mg Pb/kg injected animals, 
and an average of 300 ng/min in 3 mg Pb/kg injected animals. Other indices of renal function, 
including excretion of protein, Na, K, and Mg, were relatively constant. Plasma Zn concen- 
tration was stable in time control and low Pb-administered animals, but rose significantly after 
the higher Pb dose. Clearance experiments using 65Zn and in vitro ultrafiltration of plasma 
were performed in another series of dogs under antidiuretic conditions. Zn excretion (monitored 
by 65Zn) was sevenfold higher in Pb-treated dogs; plasma Zn concentration was slightly, but 
not significantly, elevated. Ultrafiltrable Zn concentration was 2.5-fold higher and fractional 
Zn excretion was three times higher in Pb-treated dogs. The stop-flow pattern for Zn after 
Pb treatment showed no change in the distal tubular handling of Zn, but revealed prominent 
net proximal tubular secretion of Zn in all animals, a frequency statistically different from 
that observed in control animals. Thus, acute Pb treatment in dogs produced an increase in 
urinary Zn excretion which was related both to an increase in ultrafilterable plasma Zn and 
a change in renal tubular Zn transport. The plasma concentrations of insulin and glucagon 
were not altered by lead. 
The purpose of this study was to determine 
whether lead can alter the renal excretion 
of the essential trace element, zinc. A num- 
ber of studies have documented that the 
chronic administration to rats of large quan- 
tities of zinc (either in the diet or drinking 
water) can reduce the concentrations of lead 
in blood and other tissues (Cerklewski and 
Forbes, 1976; Thawley et al., 1977; El-Gaz- 
zar et al., 1978; Cerklewski, 1979). These 
changes were associated with a protective 
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effect against the effects of lead on heme 
synthesis (Cerklewski and Forbes, 1976; 
Thawley et al., 1977). This protective effect 
is very likely due not only to the diminished 
body burden of lead, but to a direct inter- 
action between lead and zinc on certain en- 
zymes, e.g., amino levulinic acid dehydratase 
(Meredith et al., 1977; Cantrell et al., 1977; 
Davis and Avram, 1978; Mauras and Allain, 
1979). Paradoxically, the chronic adminis- 
tration of extremely large amounts of zinc 
to pigs (Hsu et al., 1975) and horses (Hsu 
et al., 1975) produced an increase in blood 
and soft-tissue lead, with either an increase 
in lead toxicity (Hsu et al., 1975) or a de- 
crease (Willoughby et al., 1972). 
To our knowledge there have been only 
two studies of the reverse relationship, i.e., 
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the effects of lead on zinc metabolism. In a 
study of mice, Seth et al. (1976) found no 
effect of lead administration on the concen- 
trations of zinc in kidney and liver; El-Gaz- 
zar et al. (1978) in a larger study with rats, 
found that the addition of 100 ppm Pb to 
drinking water caused a decrease in plasma, 
liver, and bone zinc concentrations. In nei- 
ther study was urinary excretion of zinc 
measured. 
We have previously reported that both 
lead (Vander et al., 1977; Victery et al., 
1979a,b) and zinc (Victery et al., 1981) 
undergo glomerular filtration and tubular 
reabsorption, and probably also tubular se- 
cretion. The reabsorption sites for these two 
elements are coextensive, raising the possi- 
bility that lead and zinc might compete for 
tubular transport pathways. It is also pos- 
sible that some competition might exist be- 
tween them for the low-molecular-weight 
ligands in plasma that permit their ultrafil- 
terability. These facts, taken together with 
the Pb-Zn interactions described above, sug- 
gest the hypothesis that lead would alter the 
renal excretion of zinc. To test this hypoth- 
esis, and to obtain information concerning 
the mechanism of any observed change, we 
utilized renal clearance and stop-flow tech- 
niques in anesthetized dogs. The plasma con- 
centrations of glucagon and insulin were also 
studied, since we have previously shown that 
glucagon can enhance zinc excretion (Vic- 
tery et al., 1980); a rise in the plasma con- 
centrations of these hormones might be ex- 
pected since the hepatic clearance of another 
protein hormone, renin, is reduced under the 
conditions of these experiments (Goldman 
et al., 1980). 
METHODS 
Series A. Studies were performed on 15 nonfasted 
male dogs weighing 15-21 kg. The dogs were anesthe- 
tized with pentobarbital(30 mg/kg iv, with supplements 
given as required) and were prepared surgically for renal 
clearance experiments. Both cephalic veins, a femoral 
vein, and an artery were catheterized, as was the right 
ureter via a small flank incision. After completion of 
surgery, each dog received an iv prime of p-aminohip- 
purate (PAH) and creatinine (0.25 and 0.6 g, respec- 
tively), dissolved in 20 ml saline, followed by an infusion 
of approximately 6 mg/min of each substance in a total 
of 0.21 ml isotonic saline/min. Following a I-hr equil- 
ibration period, sequential 1.5-min urine collections were 
obtained from the ureteral catheter during the next 5 
hr; each clearance value to be reported is the average 
of two consecutive 15-min collections. Twenty-milliliter 
arterial blood samples (replaced with an equal volume 
of isotonic saline) were obtained 45 min into each hr. 
All blood samples were immediately chilled and cen- 
trifuged at 4°C and the plasma was frozen. 
The first of the five hourly periods tias a baseline 
period for all dogs. Following this, five dogs (high-Pb) 
received, over 10 min, 3 mg Pb (as Pb acetate)/kg iv 
as a prime dissolved in 10 ml 5% dextrose, followed by 
an infusion of 0.57 mg Pb (as acetate)/min in 0.21 ml 
of 5% dextrose. Five dogs (low-Pb) received one-tenth 
the dose of lead (prime 0.3 mg Pb/kg, followed by in- 
fusion of 0.057 mg Pb/min), with sodium acetate added 
to obtain a solution equimolar in acetate to the high-Pb 
dose. The five remaining dogs served as time controls 
and received a sodium-acetate prime and infusion, equi- 
molar in acetate to the high-Pb dose. Throughout the 
experiment, mean arterial pressure, respiratory rate, 
hematocrit, and rectal temperatures were recorded. 
Series B. In another group of four dogs, “Zn was 
used to permit the performance of stop-flow analysis 
(Victery ef nl., 1979b) and the determination of ul- 
trafilterable zinc after the administration of Pb (3 mg/ 
kg). As described in detail elsewhere (Victery ef al., 
1980, 1981), the use of 65Zn permits measurement of 
the very small concentrations of urinary zinc present 
during the high rates of urine flow characteristic of stop- 
flow analysis; it also avoids zinc contamination of in 
vitro filtration materials and facilitates measurement of 
the very small quantity of plasma zinc which is ultra- 
filterable (Victery et al., 1980, 1981). Animals were 
prepared surgically as described for series A, except that 
one additional venous catheter was placed in a saphen- 
ous vein for infusion of 6SZn, and inulin rather than 
PAH was administered. 65Zn infusion was given in iso- 
tonic saline at 0.21 ml/mitt; it contained carrier Zn at 
10 pg Zn/kg/min and 0.30 mCi 65Zn/hr. The 65Zn in- 
fusion was begun 1.5-2 hr following the Pb dose and 
1 hr prior to the beginning of clearance collections. After 
this hour; two 15-min urine collections were obtained 
while the animals were in the same antiduretic state as 
the animals of series A. An infusion of 15% mannitol 
in isotonic saline at 0.75 ml/min/kg was then begun, 
and after stabilization of urine flow at 7-10 ml/min 
(30-40 min after starting the mannitol), two 5-min urine 
collections were obtained. During both the antidiuretic 
and mannitol clearance periods, two 15-ml vacutainers 
of nonanticoagulated blood were obtained and spun im- 
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mediately for separation of plasma. Ultrafiltrates of 
plasma were prepared (Vander er al., 1977) using 
Amicon CF-SOA (molecular weight cutoff 50,000) Cen- 
triflo membranes under 240g centrifugation. All filtrates 
were checked for protein (dipstick method) and values 
discarded if they exceeded 1 + (~20 mg/dl). Samples 
of blood, plasma, filtrate, and urine were placed in tared 
tubes for 6sZn counting. Urinary 65Zn excretion and 
percentage of plasma 65Zn which was ultrafilterable 
were determined from these counts; the increments in 
both “cold” Zn excretion and the plasma and ultrafil- 
terable concentrations of “cold” zinc produced by the 
carrier zinc infusion were calculated from the specific 
activity of the dose. No attempt was made to measure 
endogenous Zn concentrations in these experiments. 
After completion of the mannitol clearances, a stan- 
dard stop-flow procedure was performed (Malvin and 
Wilde, 1973): two or three urine samples (“free-flow” 
samples) were collected over 30 set, and immediately 
thereafter the ureteral catheter was completely occluded 
for 5 min; following release of the occlusion, urine was 
collected in 30-50 sequential aliquots, each approxi- 
mately 0.5 ml (“stop flow” [SF] samples). The concen- 
tration of 65Zn in each stop-flow samples was divided 
by the [&‘Zn] in the free-flow (FF) samples preceding 
the occlusion, and this ratio, [Zn],,/[Zn],r, was divided 
by the analogous ratio for inulin, [In]sr/[In]rF. The 
values obtained by this double ratio calculation reflect 
sequential changes in [Zn]sr relative to free-flow 
after elimination of any concentration changes due 
solely to water reabsorption. A value of this double ratio 
greater than unity signifies net zinc secretion into that 
sample during ureteral occlusion; a value less than unity 
signifies the occurrence of net Zn reabsorption from that 
sample. 
The timing and protocols of both the clearances and 
stop-flow procedures of series B were set to mimic pre- 
cisely a large series (14 dogs) of time control experi- 
ments performed simultaneously in our laboratory in 
association with other studies (Victery et al., 1980, 
1981); these 14 dogs had received precisely the same 
surgical preparation and infusions, and had clearances 
and stopflow analysis performed at exactly the same 
length of time after the onset of the infusion of 65Zn 
and inulin. Accordingly, this group of animals has been 
used as the control group to compare the effects of lead 
on the present dogs of series B. Such a control group 
is necessary since stop-flow analysis cannot be per- 
formed both before and after lead exposure, i.e., the Pb- 
exposed dogs cannot act as their own controls. 
Analytical merhods. Urinary and plasma concentra- 
tions of zinc were measured by atomic absorption (Var- 
ian Instruments, Model 375,214 nm, slit = 0.5); urinary 
magnesium concentration was also measured by atomic 
absorption (202.5 nm, slit = 0.5). Urine sodium and 
potassium concentrations were determined by game 
photometry. Urinary and/or plasma concentrations of 
protein, creatinine, PAH, and inulin were determined 
by standard methods described previously (Victery et 
al., 1979a). Plasma concentrations of glucagon and in- 
sulin were measured by radioimmunoassay (Hayaski et 
al., 1977; Pek et al., 1972). 
The values for excretion of zinc, magnesium, protein, 
sodium, and potassium, and for glomerular filtration 
rate (GFR) and effective renal plasma flow (ERPF) 
were averaged for each OS-hr period (two consecutive 
15-min collections) and treated as a single value. 
All grouped data are presented as the mean -+ one 
standard error (SE). Statistical comparisons in the Se- 
ries A experiments are between experimental and time 
control groups, using regression analysis with Scheffe 
allowances for multiple comparisons. In series B, dif- 
ferences between Pb-treated and control animals were 
compared using Student’s t test for group mean, or x2 
for frequency data. 
RESULTS 
Series A 
Figure 1 depicts the pattern of urinary 
zinc excretion over time in each of the three 
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FIG. 1. Changes in urinary zinc excretion for the three 
groups of dogs are plotted against time after adminis- 
tration of the Pb or acetate prime. Excretion in the 
baseline half-hour clearance period (-0.5-o hr) has 
been set at zero, with successive time points plotted as 
the mean change from this baseline value (control dogs 
= 88.9 f  30.9,low-Pb = 46.5 + 7.0 and high-Pb = 49.5 
rt_ 3.8). See text for statistical analysis of data. 
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experimental groups of Series A. For clarity, 
excretion during the baseline clearance pe- 
riod (-0.5-o hr) has been set at zero; values 
of subsequent collections are the mean 
change (+ 1 SE) in Zn excretion for each 
group. Zn excretion, in nanograms per min- 
ute, for the baseline clearances for control 
dogs averaged 88.9 f 30.9,low-Pb animals 
= 46.5 f 7.0, and high-Pb 49.5 f 3.8. There 
were no significant differences between these 
baseline group means; the larger mean for 
the control animals was attributable pri- 
marily to one animal whose initial zinc ex- 
cretion was 200 ng/min. Over the remaining 
4-hr time course of the experiment, zinc ex- 
cretion in control animals tended to de- 
crease; the mean decrease at 4 hr was 36 
ng/min. In contrast, zinc excretion in both 
Pb-treated groups rose dramatically and 
continuously beginning 0.5 hr after lead ex- 
posure. Four hours after the high-Pb dose, 
zinc excretion was 294.3 f 56.0 ng/min 
above the baseline clearance value (a sev- 
enfold increase). Four hours after the low- 
Pb dose, zinc excretion was 138.8 f 51.4 
ng/min greater than before Pb exposure (a 
fourfold increase). Comparison of the slopes 
of the curves for treated animals to that of 
controls yielded a p value for the low dose 
of <O.Ol, and <0.0002 for the high dose. 
Figure 2 presents the changes in plasma 
zinc concentrations; again, all values have 
been normalized with respect to the first 
(baseline) values; there were no differences 
between the baseline group means (control 
= 65.0 2 4.5 pg/lOO ml; low dose = 70.6 
? 7.4; high dose = 67.6 & 14.5). Plasma 
zinc in control animals fell slowly through- 
out the experiment, and at 4 hr was about 
20 pg/ 100 ml lower than the baseline value. 
We have consistently observed this pattern 
in control animals; the cause is unknown but 
may relate to the trauma of anesthesia and 
surgery. Plasma zinc in animals which re- 
ceived the low dose of Pb tended to remain 
quite stable over time, and this pattern was 
not significantly different from that for the 
time controls. The larger dose of Pb pro- 
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FIG. 2. Changes in plasma zinc concentration are 
plotted against time after Pb or acetate prime. Values 
for the baseline blood collection (-0.5-O hr) have been 
normalized to zero, with subsequent values plotted as 
the change from this baseline value (control dogs = 65.0 
+ 4.5 pg/lOO ml, low Pb = 10.6 + 1.4, high Ph = 67.6 
+ 14.5). See text for statistical analysis of data. 
duced a marked, significant (p < 0.01) rise 
in plasma zinc concentration over time; by 
1 hr, there was a 64 pg/ 100 ml increase, and 
by 4 hr, the increase was 113 pg/lOO ml 
(a two- to threefold increase). 
The increase in plasma zinc might be due 
to displacement of zinc from erythrocytes to 
plasma. To test this possibility, a small sam- 
ple of whole anticoagulated blood was re- 
moved from a dog before Pb treatment. To 
one aliquot of the blood, sufficient Pb acetate 
was added in vitro to increase Pb concen- 
tration by 400 pg/ 100 ml (the estimated 
blood concentration of lead present 2 hr after 
the lead prime). Both aliquots were incu- 
bated at 37°C for 1 hr, then centrifuged to 
separate the plasma. There was no difference 
in plasma zinc concentrations between the 
two aliquots. 
Other renal function data obtained in 
these experiments are summarized in Table 
1. There were no significant effects of Pb on 
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nesium, sodium, and potassium; if anything, 
there was a slight (but not significant) ten- 
dency for sodium excretion to decline in the 
last collection period after high Pb dose. 
Since most plasma zinc is protein bound, in- 
creased excretion of protein could contribute 
to increased urinary zinc levels; however, 
urinary protein excretion was similar in the 
three groups of animals (Table 1). 
GFR was stable in the control and low- 
dose animals, but fell significantly in high- 
dose animals by 3 to 4 hr after Pb exposure. 
A similar decrease was observed for ERPF 
at 3 to 4 hr. There were no differences in 
urine flow rates between the treatment 
groups; the tendency for urine flow to be 
elevated at 3 and 4 hr in the high-Pb group 
was due to very high values observed in one 
animal at those times. Throughout the ex- 
periment there were no changes within or 
between groups in mean arterial pressure, 
respiratory rate, hematocrit, or rectal tem- 
perature. 
The data for the plasma concentrations 
of glucagon and insulin are summarized in 
Fig. 3. For the time controls, plasma glu- 
cagon increased slightly in the last 2 hr, 
whereas insulin generally decreased. There 
was a tendency for plasma glucagon to in- 
crease over time in both Pb-treated groups 
(the increase over baseline was approxi- 
mately 50% by hours 3 and 4) but the ob- 
served differences between this pattern and 
that of the time control group were not sta- 
tistically significant, either by regression 
analysis of the entire curves or by analysis 
of variance at each time. The jump in glu- 
cagon at 4 hr in the high-Pb group was due 
to a very large increase in one of the five 
animals. Plasma insulin concentrations re- 
mained stable throughout the experiment in 
the Pb-treated groups and were not signifi- 
cantly different from those of the time con- 
trol groups. 
Series B 
Clearance data obtained for antidiuretic 
dogs using 65Zn are summarized in Fig. 4; 
I5 
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FIG. 3. Changes in plasma glucagon concentration 
(upper panel) and plasma insulin concentration (lower 
panel) for the three groups of animals. All values are 
presented as the change from the value during baseline 
collection period at 0 hr after Pb prime (baseline insulin 
values for control dogs = 21.1 + 4.5, low-Pb = 19.1 
f  6.0, and high-Pb = 19.0 f  4.5, baseline glucagon 
values for control dogs = 133.5 pm 47.1,low-Pb = 205.0 
+ 39.3, and high-Pb = 2 15.2 + 15.9). See text for sta- 
tistical analysis of data. 
each panel compares values obtained from 
control dogs with those from dogs 3 hr after 
Pb exposure. Zn excretion (Fig. 4A) was 7.6- 
fold higher in the Pb-treated dogs; this in- 
crement is comparable to the rise in endog- 
enous zinc excretion seen in Series A dogs. 
It should be reemphasized that all data for 
Series B dogs represent only the increment 
in Zn excretion caused by infusion of carrier 
Zn along with the 65Zn. The increment in 
plasma zinc (Fig. 4B) caused by the Zn in- 
fusion was not statistically significant. The 
increment in ultrafilterable zinc concentra- 
tion (Fig. 4C) produced by the zinc infusion 
was two and one-half times higher in Pb- 
exposed animals (p < 0.01); the percentage 
of the increment in plasma zinc which was 
ultrafilterable was not different between the 
two groups. The clearance of ultrafilterable 
65Zn was 1.67 f 0.30 ml/min in control dogs 
and 4.75 + 1.37 after Pb exposure; this dif- 
ference was significant (p < 0.05). Frac- 
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FIG. 4. Clearance data obtained in control dogs 
(shown in open bars) and in Pb-treated dogs (hatched 
bars) using 65Zn infusion with 10 ng carrier Zn/kg/min. 
All values are presented as the average increment 
( + 1 SE) in Zn values calculated from the specific ac- 
tivity of the infused solution. See text for details. (A) 
Increment in urinary Zn excretion; (B) increment in 
plasma Zn concentration; (C) increment in ultrafilter- 
able Zn concentration; (D) fractional excretion of Zn 
(c”It-z.Iccr). 
tional zinc excretion (the ratio of Cultzn to 
C,,), illustrated in Fig. 4D, was threefold 
higher (p < 0.02) in the Pb-exposed dogs 
than in the controls. The effects of mannitol 
diuresis on fractional zinc excretion in con- 
trol and Pb-exposed dogs are summarized 
in Fig. 5. In control dogs, mannitol (an os- 
motic diuretic) increased fractional excre- 
tion from 0.044 f 0.008 to 0.100 f 0.020 
(p c 0.02); in Pb-exposed dogs, fractional 
excretion was already elevated (0.123 
+ 0.025) and mannitol produced only a 
small further (nonsignificant) elevation to 
0.142 f 0.022. Ultrafilterable zinc concen- 
trations in both control and Pb-exposed an- 
imals were not altered by mannitol. 
Stop-flow analysis permits crude localiza- 
tion of sites of tubular reabsorption or se- 
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FIG. 5. The mean fractional excretion of Zn (+l SE) 
for control and Pb-treated animals during antidiuresis 
and osmotic diuresis (mannitol). Statistical comparison 
is discussed in the text. 
vious studies (Victery et al., 1981), we have 
reported that control stop-flow patterns for 
Zn invariably showed net reabsorption in the 
distal nephron but not the proximal nephron; 
proximal reabsorption was seen only during 
infusion of citrate or histidine. The stop-flow 
pattern dipicted in Fig. 6 is typical of those 
obtained after Pb exposure in all four dogs. 
Prominent net Zn reabsorption occurred in 
the distal nephron segment corresponding to 
that for the distal minimum for sodium; for 
the control and Pb-treated groups, the mean 
“double ratios” (Zn/In) at the nadir of the 
Zn reabsorptive dip averaged 0.24 + 0.07 
and 0.31 f 0.04, respectively, values which 
are not significantly different from each 
other. The absolute concentrations of the 
carrier Zn administered with 65Zn at the 
nadirs were 0.062 f 0.019 vs 0.283 -+ 0.130 
rig/ml, also not significantly different. The 
results, therefore, fail to demonstrate Pb-in- 
duced inhibition of distal Zn reabsorption. 
The stop-flow pattern for Zn shown in Fig. 
6 also reveals prominent net proximal neph- 
ron secretion of Zn; the double ratio in this 
experiment reached a maximum value of 
1.75 and then returned to preocclusive free- 
flow values. After Pb exposure, definite net 
secretion of Zn by the proximal nephron was 
observed in all four animals (double 
ratio = 1.94, 1.75, 1.6, and 1.32). In con- 
trast, definite net secretion occurred in only 
4 of 14 control animals. This difference in 
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FIG. 6. A typical stop-flow pattern obtained 3 hr after 
Pb treatment (approximately 40 min after initiation of 
mannitol diuresis). See text for description of Zn pat- 
tern. The sodium concentration pattern (not plotted 
here) provides coarse localization of nephron segments 
in that the minimal sodium concentration (about 3.5 ml 
in Fig. 6), ie., the point of maximal reabsorption, cor- 
responds to fluid trapped during ureteral occlusion in 
distal portions of the nephron (probably including col- 
lecting duct, distal tubule, and the ascending loop of 
Henle); the beginning of the plateau in sodium concen- 
tration (approximately 1 l-l 2 ml in Fig. 6) at its preoc- 
elusive values is presumed to represent fluid trapped only 
in the proximal portions of nephrons during occlusion. 
frequency of occurrence of net proximal se- 
cretion is highly significant (P < 0.01 by 
x2 analysis). 
DISCUSSION 
These experiments demonstrate that the 
acute iv administration of lead to anesthe- 
tized dogs causes a dose-dependent, marked 
increase in urinary excretion of zinc. In this 
study, the effect was specific, in that there 
were no associated changes in urine flow or 
in the excretion of another divalent cation 
(magnesium) or of two monovalent cations 
(sodium and potassium). We have previously 
reported (Mouw et al., 1978) that, under 
similar experimental conditions, 3 mg Pb/ 
kg produced significant increases in the uri- 
nary excretion of potassium and calcium and 
an increased sodium excretion of borderline 
significance (magnesium was not previously 
studied). We have no explanation for the 
failure to observe these changes in the pres- 
ent experiments; however, it must be em- 
phasized that the previously observed changes 
in the other cations were, proportionally, of 
much lesser magnitude (approximately two- 
fold) than the present changes in zinc ex- 
cretion (seven- to eightfold) at the same dose 
of lead. 
What are the mechanisms for the Pb-in- 
duced changes in zinc excretion? We have 
previously shown that the urinary excretion 
of zinc is the result of glomerular filtration, 
tubular reabsorption, and, possibly, tubular 
secretion (Victery et al., 198 1). Thus, the 
effect(s) could, theoretically, be on GFR, 
ultrafilterable zinc concentration, or the tu- 
bular transport pathways. An increase in 
GFR can be ruled out since GFR either re- 
mained unchanged or, at the high dose, de- 
creased. Changes in the filtration of protein 
(carrying bound zinc) also seem very un- 
likely since protein excretion was not altered 
by lead. 
Plasma zinc concentration did rise mark- 
edly at the higher dose of lead and this raised 
the strong possibility that ultrafilterable 
zinc, the important variable, might also have 
risen. To test this possibility, we performed 
the 6SZn experiments. The rationale for this 
approach has been described in detail else- 
where (Victery et al., 1980); the crucial 
point validating its use is that Pb increased 
urinary excretion of acutely administered 
6sZn to essentially the same degree that it 
increased urinary excretion of endogenous 
zinc. This documents that the 65Zn had 
equilibrated adequately with whatever pools 
of zinc were contributing to Pb-alterable 
zinc excretion. The ultrafilterable data in- 
dicated that, at least at the higher dose, Pb 
did, indeed, elevate ultrafilterable zinc con- 
centration, a phenomenon which should con- 
tribute to increased excretion. However, 
even at the higher dose of lead, the increase 
in ultrafilterable zinc was proportionally 
much less than the rise in zinc excretion; the 
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resulting large increase in fractional excre- 
tion of zinc is a strong indication that a 
change in tubular transport also plays a role 
in the induced elevation of zinc excretion. 
The source of the increased plasma and ul- 
trafilterable zinc induced by lead is unknown 
but is unlikely to be the erythrocytes, as 
demonstrated by the in vitro experiment de- 
scribed in the methods section. 
Stop-flow analysis was used to evaluate 
the possible tubular site influenced by lead 
and whether reabsorption was being inhib- 
ited or secretion stimulated. The major ef- 
fect was clearly on the proximal nephron; 
the stop-flow patterns document the exis- 
tence of prominent proximal secretion of 
zinc in all Pb-treated dogs, in contrast to the 
much lower frequency of such secretion seen 
in control dogs. However, this finding does 
not conclusively prove that increased prox- 
imal secretion is the effect produced by lead; 
decreased proximal reabsorption is just as 
likely a possibility. If bidirectional transport 
normally exists for zinc in the proximal 
nephron (Victery et al., 198 1 ), inhibition of 
reabsorption would permit secretion, unop- 
posed, to become manifest. Accordingly, the 
present data do not permit a distinction be- 
tween Pb-induced stimulation of secretion 
or inhibition of reabsorption. Theoretically, 
the latter would seem the more likely, as- 
suming that lead and zinc compete for a 
transport pathway. Indirect evidence also 
favoring inhibition of proximal reabsorption 
is the fact that lead had relatively little fur- 
ther enhancing effect on zinc excretion when 
the latter had already been raised by man- 
nitol diuresis. 
Whether lead influences proximal zinc 
transport indirectly or via a direct renal ef- 
fect is not answered by the present experi- 
ments. They do, however, rule out the pos- 
sibility that increased plasma glucagon or 
decreased plasma insulin is responsible, since 
these hormones showed little if any, altera- 
tion during Pb exposure. This failure to in- 
crease is, however, of considerable interest 
in another context; it suggests that the abil- 
ity of lead to block the hepatic clearance of 
renin (Goldman et al., 1980), another pro- 
tein hormone, may be a highly specific effect. 
Finally, the most important question for 
future investigation raised by these experi- 
ments is whether chronic exposure to low 
doses of lead might similarly elevate zinc 
excretion. Such an effect would be in addi- 
tion to any Pb-induced inhibition of gas- 
trointestinal zinc absorption and might im- 
portantly contribute to the development of 
zinc deficiency. 
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